Stay updated with breaking news from Markus Warmuth. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
10.11.2022 - – Initiated Patient Dosing in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors – – Progressed VAV1 Molecular Glue Degrader Program into Lead Optimization – BOSTON, Nov. 10, ...
She previously served as SVP, head of business development.
Press release content from Business Wire. The AP news staff was not involved in its creation. Monte Rosa Therapeutics Announces $95 Million Series C Financing to Accelerate Next-generation Protein Degradation Platform March 12, 2021 GMT BOSTON--(BUSINESS WIRE)--Mar 12, 2021-- Monte Rosa Therapeutics, a biotechnology company focused on discovering and developing precision medicines that degrade disease-causing proteins, announced today the closing of a $95 million Series C financing. The proceeds will be used to advance its lead development candidate into the clinic, accelerate pipeline growth...
RTW Participates in $95 Million Financing Round in Monte Rosa Therapeutics RTW Venture Fund Limited (the "Company"), the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note the announcement by Monte Rosa Therapeutics, Inc. ("Monte Rosa") on 12 March 2021 of its completion of a $95 million Series C financing round. The Company, alongside other investment vehicles of RTW Investments, LP (the "Investment Manager"), confirms that it participated in the financing rou...
Published: Feb 08, 2021 Silvia Buonamici, Ph.D., BOSTON--(BUSINESS WIRE)-- Monte Rosa Therapeutics, a biotechnology company focused on discovering and developing precision medicines that degrade disease-causing proteins, announced today the appointments of Owen Wallace, Ph.D., as Chief Scientific Officer and Silvia Buonamici, Ph.D., as Senior Vice President, Drug Discovery Biology, as the company continues to expand its executive leadership team. Drs. Wallace and Buonamici will oversee the research and development of the company’s pipeline of molecular glue degrader programs. “A...